Pharmacotherapy consideration of thrombolytic medications in COVID-19-associated ARDS
Abstract Background In late 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which is responsible for coronavirus disease (COVID-19), was identified as the new pathogen to lead pneumonia in Wuhan, China, which has spread all over the world and developed into a pandemic.Despite the over 1 year of pandemic, due to the lack of an